Omeros

Stock exchange concept
Biotech

Omeros stock up after data analysis spurs BLA resubmission plan

Given the results, Omeros hopes the anti-MASP-2 antibody narsoplimab will become the first treatment on the market in the indication.
Gabrielle Masson Dec 19, 2024 10:54am
failure crash no fail rocket cancelled end

Omeros stops kidney disease phase 3 after interim review fail

Oct 16, 2023 8:45am
reins rider cowboy horse steady hands saddle

Omeros saddles up for 2nd charge at transplant drug approval

Mar 14, 2023 9:30am
clock calendar time late delayed alarm

Omeros' Hail Mary throw for blood clot med delayed at FDA

Aug 17, 2022 11:21am
FDA Building 2

FDA rejects Omeros drug over difficulties estimating its effect

Oct 18, 2021 8:15am
Seattle

Omeros hits endpoint in pivotal stem cell transplant study

Dec 4, 2019 8:38am